Oxfendazole (Synanthic)

Oxfendazole, marketed under the brand name Synanthic, is a broad-spectrum benzimidazole anthelmintic approved for the treatment and control of internal parasites in cattle. As a member of the benzimidazole class of dewormers, commonly known as white dewormers, oxfendazole has established itself as an effective tool for managing gastrointestinal roundworms and lungworms in bovine operations. The drug represents an important option within the benzimidazole category, offering reliable parasite control with characteristics that complement other available anthelmintics in comprehensive parasite management programs.

The mechanism of action of oxfendazole follows the established benzimidazole pathway of selective binding to parasitic beta-tubulin protein. This binding disrupts microtubule formation and function within parasite cells, impairing critical processes including nutrient absorption, cellular transport, and cell division. The resulting metabolic disruption and energy depletion lead to parasite death over a period following treatment. Oxfendazole demonstrates selectivity for parasitic tubulin over mammalian tubulin, providing the basis for its safety margin in treated cattle. Interestingly, oxfendazole is metabolically interrelated with fenbendazole; oxfendazole is reduced in the body to fenbendazole, which is then re-oxidized to oxfendazole sulfone. This metabolic cycling contributes to the sustained antiparasitic activity of both drugs.

Oxfendazole is available as an oral suspension formulation designed for administration as a drench to individual cattle. This liquid formulation allows for precise weight-based dosing, ensuring each animal receives an appropriate amount of medication based on its body weight. The suspension is ready to use after thorough shaking to ensure uniform distribution of the active ingredient. Unlike some other anthelmintics available in multiple formulation types, oxfendazole's primary availability as an oral drench emphasizes the importance of accurate individual dosing for optimal efficacy and resistance management.

From a regulatory standpoint, oxfendazole (Synanthic) is approved by the FDA for use in cattle, including beef cattle and non-lactating dairy cattle. The drug is classified as over-the-counter, making it accessible through agricultural supply retailers without requiring a veterinary prescription. However, the increasing challenges posed by anthelmintic resistance make veterinary guidance increasingly valuable when incorporating oxfendazole into parasite control programs. Strategic drug selection based on regional resistance patterns, fecal egg count monitoring, and efficacy testing helps ensure continued effectiveness of this valuable medication.

Oxfendazole possesses broad-spectrum efficacy against the economically important gastrointestinal nematodes and lungworms that affect cattle, making it a valuable component of integrated parasite management programs in beef and dairy operations. The drug is approved for the removal and control of numerous adult and larval stage parasites that impact cattle health and productivity. Primary labeled indications include treatment of lungworms (Dictyocaulus viviparus), brown stomach worm (Ostertagia ostertagi) including inhibited fourth-stage larvae, barberpole worm (Haemonchus contortus and Haemonchus placei), small stomach worm (Trichostrongylus axei), cooperia species (Cooperia oncophora, Cooperia punctata, Cooperia surnabada), hookworm (Bunostomum phlebotomum), threadnecked intestinal worm (Nematodirus helvetianus), small intestinal worm (Trichostrongylus colubriformis), and nodular worm (Oesophagostomum radiatum).

One of the most clinically significant applications of oxfendazole is its efficacy against arrested (inhibited) fourth-stage larvae of Ostertagia ostertagi. These dormant larvae represent a survival adaptation that allows the parasite to persist within the host's gastric glands during environmental conditions unfavorable for completing its life cycle. The larvae can remain inhibited for extended periods, with their synchronized emergence and development causing the potentially devastating syndrome known as Type II ostertagiasis. This condition, occurring most commonly in late winter and early spring in temperate climates, can cause severe weight loss, diarrhea, and mortality if heavy larval populations emerge simultaneously. Oxfendazole's ability to eliminate these inhibited larvae makes it particularly valuable for strategic winter or early spring treatments targeting this phenomenon.

Beyond treatment of clinically apparent parasitism, oxfendazole plays an important role in preventive and strategic deworming programs in cattle operations. Strategic treatment timing based on seasonal parasite dynamics and regional epidemiology helps reduce pasture contamination and protects susceptible animals from acquiring heavy parasite burdens. Common strategic treatment points include housing in fall (targeting adult parasites and preventing further pasture contamination), mid-winter (addressing inhibited larvae before emergence), and spring turnout (reducing initial pasture contamination). The specific timing and frequency of strategic treatments should be determined based on regional conditions, farm history, and monitoring data.

The spectrum of activity of oxfendazole covers the major gastrointestinal nematodes and lungworms of cattle but does not extend to liver flukes or tapeworms. Operations facing fluke challenges require combination approaches using oxfendazole for nematode control alongside specific flukicides. This spectrum limitation is shared with fenbendazole, while albendazole offers additional fluke efficacy within the benzimidazole class. Understanding the specific parasite challenges present on each operation allows for appropriate drug selection and combination strategies.

Extra-label use of oxfendazole in species other than cattle may occur under veterinary supervision, though the drug's primary utility and approval center on bovine applications. When considering use in other ruminants such as sheep or goats, the different pharmacokinetic profiles in these species must be considered, and veterinary guidance is essential for establishing appropriate doses and withdrawal times. The extra-label use regulations require a valid veterinarian-client-patient relationship and appropriate record keeping.

Achieving optimal efficacy with oxfendazole requires precise weight-based dosing and proper oral administration technique. The labeled dose of oxfendazole for cattle is 4.5 mg/kg body weight (2.05 mg/lb), administered as a single oral drench. This dose provides effective control of susceptible adult gastrointestinal roundworms, lungworms, and inhibited fourth-stage Ostertagia larvae. Accurate determination of body weight is essential for calculating the appropriate dose volume, as underdosing compromises efficacy and promotes resistance development, while significant overdosing unnecessarily increases drug exposure and may affect safety margins.

Cattle should be weighed using scales when available, or their weights should be estimated using established methods such as weight tapes calibrated for cattle body conformation. When treating groups of cattle without individual weighing, animals should be sorted into weight categories and dosed according to the heaviest animal in each group. This approach ensures that no animal receives less than the required dose while keeping overdosing of smaller animals within acceptable limits. For operations with significant weight variation within the herd, sorting into multiple dosing groups improves treatment precision.

Oxfendazole oral suspension should be shaken thoroughly before each use to ensure uniform distribution of the suspended active ingredient throughout the product. Settlement of drug particles during storage is normal, and failure to remix the product adequately before dosing may result in variable drug delivery, with early doses potentially containing less medication than intended and later doses containing more. After shaking, the appropriate volume should be measured using a calibrated drench gun or dosing syringe. Equipment should be checked regularly for accuracy and recalibrated as needed to ensure consistent dose delivery.

Proper administration technique ensures complete dose delivery and minimizes complications. The drench should be administered over the back of the tongue, placing the delivery nozzle in a position that stimulates swallowing and prevents the product from being spit out or aspirated. Cattle should be appropriately restrained to allow safe access to the mouth and to prevent sudden head movements that could cause injury to the animal or handler. The drench gun nozzle should be smooth and undamaged to avoid oral trauma. After administration, the animal should be observed briefly to confirm swallowing before release.

The treatment duration for oxfendazole is a single dose under most circumstances. The pharmacokinetic properties of the drug allow for effective parasite control with once-only administration for labeled indications. Extended treatment protocols are not typically indicated for oxfendazole in cattle. Repeat treatments may be necessary based on reinfection from contaminated pastures, but this represents new treatment events rather than extended dosing for a single infestation. The timing and frequency of repeat treatments should be determined based on fecal egg count monitoring and regional parasite pressure rather than arbitrary calendar-based scheduling.

Meat withdrawal time for oxfendazole in cattle is 7 days. Animals must not be slaughtered for human consumption within this period following treatment to ensure drug residues have declined below tolerance levels. Oxfendazole should not be used in female dairy cattle of breeding age due to milk residue concerns; there is no established milk withdrawal time for the drug. This restriction necessitates alternative anthelmintic selection for lactating dairy cattle requiring parasite treatment. Accurate treatment records documenting the date of administration, identity of treated animals, product used, and dose given must be maintained to ensure withdrawal compliance and demonstrate food safety diligence.

Oxfendazole is generally well tolerated in cattle when administered according to label directions, reflecting the favorable safety profile characteristic of the benzimidazole anthelmintic class. Adverse reactions to properly dosed treatments are relatively uncommon, and the drug has established a track record of safe use in bovine operations over many years. However, as with any medication, potential side effects exist and awareness of possible reactions enables appropriate monitoring and management should they occur.

The most commonly observed effects following oxfendazole administration are mild and transient gastrointestinal disturbances. Some cattle may exhibit temporary softening of feces or mild diarrhea in the days following treatment. This effect is generally attributed to the die-off and expulsion of intestinal parasites and the associated intestinal response rather than direct toxicity of the medication itself. As parasites are eliminated from the gut, temporary changes in the intestinal environment may affect fecal consistency. These changes typically resolve spontaneously within several days without requiring intervention. Animals carrying heavier initial parasite burdens may show more pronounced post-treatment effects.

Transient decreases in feed intake and mild lethargy have been reported occasionally after oxfendazole treatment. These effects are generally associated with the physiological adjustments accompanying parasite elimination and typically resolve within 24 to 48 hours. The release of antigens and other materials from dying parasites may trigger mild systemic effects that manifest as temporary reduced activity or appetite. Animals showing prolonged depression, fever, or significant appetite suppression warrant closer examination to rule out concurrent conditions or complications.

Injection site reactions are not applicable to oxfendazole since the drug is administered orally. However, complications associated with oral drenching procedures can occur with any drench product. Aspiration pneumonia is a rare but serious potential complication if product is inadvertently delivered into the airways rather than the esophagus. Proper head positioning during administration, with the animal's head held at a natural angle rather than elevated, minimizes aspiration risk. Mechanical trauma to the oral cavity or pharynx from the dosing equipment is another potential administration-related complication. Using appropriate equipment in good repair and employing gentle technique reduces this risk.

Serious adverse effects from oxfendazole are rare in cattle receiving appropriate doses. The benzimidazole class generally demonstrates wide safety margins, and oxfendazole follows this pattern. Massive overdoses exceeding several times the recommended dose may result in more significant effects, but such exposures are uncommon with proper dosing practices. Idiosyncratic hypersensitivity reactions, while rare, may occur in individual animals regardless of dose. Signs of allergic reaction might include facial swelling, urticaria, or respiratory distress. Animals exhibiting such signs should receive prompt veterinary attention. The die-off of very heavy parasite burdens can occasionally cause more pronounced inflammatory responses or endotoxemia, particularly in heavily parasitized animals. Such reactions are generally self-limiting but may warrant supportive care in severe cases.

Understanding the contraindications for oxfendazole use is essential for safe and appropriate parasite management in cattle operations. The most significant practical contraindication is use in female dairy cattle of breeding age. Oxfendazole does not have an established milk withdrawal time, and the potential for drug residues to appear in milk following treatment creates an unacceptable food safety risk. This restriction effectively excludes oxfendazole from use in lactating dairy cattle and dairy heifers approaching breeding age whose milk will enter the food chain. Dairy operations requiring anthelmintic treatment in these animals must select alternative products with established milk withdrawal periods.

The safety of oxfendazole during pregnancy in cattle has not been as extensively characterized as for some other benzimidazoles. While the drug is not labeled with specific pregnancy contraindications like those applied to albendazole, prudent practice suggests avoiding unnecessary medication during pregnancy when possible. When parasite control is necessary in pregnant cattle, consultation with a veterinarian regarding the most appropriate drug choice for the specific circumstances is advisable. Some practitioners preferentially select fenbendazole for pregnant animals due to its more extensively documented safety profile during gestation.

Oxfendazole should not be administered to cattle with known hypersensitivity to benzimidazole anthelmintics. While true allergic reactions to this drug class are rare, animals that have previously exhibited adverse hypersensitivity responses following benzimidazole administration should not receive oxfendazole. Cross-sensitivity among benzimidazoles is expected given their structural similarities. Alternative anthelmintic classes should be selected for animals with documented benzimidazole hypersensitivity.

Use in severely debilitated or clinically ill cattle requires careful consideration and veterinary guidance. While not absolutely contraindicated, animals in very poor body condition may have altered drug handling characteristics and may be more susceptible to adverse effects. The stress of handling and treatment may pose additional risks to compromised animals. In heavily parasitized animals with poor condition scores, the rapid elimination of large parasite burdens can occasionally cause transient clinical deterioration before improvement is seen. Supportive care concurrent with treatment may be beneficial in such cases. For cattle requiring extra-label use of oxfendazole in situations outside labeled parameters, veterinary supervision is essential to ensure appropriate dosing and withdrawal considerations.

Oxfendazole demonstrates generally favorable compatibility with other medications and feed additives commonly used in cattle production. Drug interactions of clinical significance are relatively uncommon with this benzimidazole anthelmintic. However, understanding potential interactions helps optimize treatment protocols and ensures safe concurrent use with other products when multimodal therapy is needed.

The combination of oxfendazole with other benzimidazole anthelmintics is not recommended as it provides no therapeutic advantage. All benzimidazoles share the same mechanism of action through beta-tubulin binding, so concurrent use does not produce additive efficacy and may unnecessarily increase drug exposure without benefit. However, strategic rotation between oxfendazole and anthelmintics from other drug classes forms a cornerstone of resistance management. The goal of rotation is to reduce selection pressure for resistance to any single drug class by alternating mechanisms of action over time. Resistance monitoring through fecal egg count reduction testing helps guide rational rotation decisions.

Oxfendazole can be safely used in cattle receiving ionophore feed additives such as monensin (Rumensin), lasalocid (Bovatec), and laidlomycin propionate. Unlike some other medications, benzimidazoles do not potentiate ionophore toxicity or demonstrate problematic interactions with these commonly used coccidiostats and growth promotants. Cattle feeders and producers using medicated feeds containing ionophores can administer oxfendazole treatments without concern for dangerous interactions. Nevertheless, all medications being administered should be documented and communicated to veterinarians providing treatment advice.

Vaccine administration can generally proceed without concern for interactions with oxfendazole. No immunosuppressive effect from oxfendazole administration has been documented that would compromise vaccine efficacy. When multiple interventions are scheduled during a single handling event, oxfendazole can be administered alongside routine vaccinations. Some practitioners prefer to separate anthelmintic treatments from vaccinations by several days as a practical measure to simplify monitoring for adverse reactions, but this is not based on pharmacological incompatibility. The metabolic interrelationship between oxfendazole and fenbendazole (oxfendazole is reduced to fenbendazole in vivo) means that sequential treatment with these two drugs would not provide rotation benefits, as both ultimately achieve their effect through the same active compound. True rotation requires drugs from different anthelmintic classes with distinct mechanisms.

Effective and responsible use of oxfendazole requires attention to several important precautions that protect animal welfare, ensure food safety, and preserve the long-term utility of this anthelmintic. Human safety during product handling deserves appropriate attention, particularly for individuals who handle the medication frequently. While oxfendazole is not classified as highly hazardous, prudent handling practices should be observed. Direct skin contact with the product should be minimized, and hands should be washed thoroughly after handling. Eating, drinking, and smoking should be avoided during product handling. Pregnant women may choose to avoid handling benzimidazole anthelmintics as a general precaution, though significant risk from incidental occupational exposure has not been established.

Food safety considerations are paramount when treating food-producing animals. Strict adherence to the 7-day meat withdrawal period is mandatory to ensure drug residues have declined to acceptable levels before treated cattle enter the food chain. Animals must not be slaughtered for human consumption within this withdrawal period. The prohibition on use in dairy cattle of breeding age due to lack of established milk withdrawal must be observed without exception. Treatment records documenting the identity of treated animals, date of treatment, product used, dose administered, and route of administration are essential for demonstrating compliance with food safety requirements. These records may be required by regulatory authorities, packers, or food safety certification programs.

Anthelmintic resistance poses an escalating challenge to cattle parasite management, and responsible oxfendazole use must incorporate resistance mitigation strategies. Benzimidazole resistance is documented in cattle parasites in various regions and may be more common than recognized due to limited monitoring. Key practices for preserving oxfendazole efficacy include treating only when indicated based on evidence of parasitism rather than calendar-based scheduling, using accurate doses based on actual body weights, ensuring complete dose delivery through proper administration technique, maintaining refugia populations of susceptible parasites through selective treatment strategies, and monitoring treatment efficacy through fecal egg count reduction testing. Detection of emerging resistance before it becomes established allows timely intervention and alternative drug selection.

Environmental considerations warrant inclusion in anthelmintic use decisions. Drug residues excreted in feces following treatment may impact dung-inhabiting organisms that provide ecological services including dung degradation and nutrient cycling. While benzimidazoles are generally considered less environmentally persistent than certain other anthelmintic classes, minimizing environmental loading through targeted treatment of animals with demonstrated need rather than blanket whole-herd treatment supports environmental stewardship. This approach also reduces selection pressure for resistance development.

Storage and handling practices maintain product integrity throughout the shelf life. Oxfendazole suspension should be stored at controlled room temperature protected from temperature extremes and direct sunlight. Thorough shaking before each use ensures uniform drug distribution in the suspension. Multi-dose containers should be managed to prevent contamination, and partially used containers should be used in a timely manner. Expired products should not be used and must be disposed of properly according to applicable regulations.

Proper storage and handling of oxfendazole products ensures maintenance of drug potency and product quality throughout the shelf life while supporting safe use in cattle operations. Oxfendazole oral suspension (Synanthic) should be stored at controlled room temperature, typically between 59-86°F (15-30°C), protected from both extreme heat and freezing temperatures. Exposure to temperature extremes can affect the physical stability of the suspension and may impact drug efficacy. The product should be stored in a secure location away from direct sunlight and inaccessible to children and non-target animals. Veterinary medications should be stored separately from food products and clearly labeled to prevent accidental misuse or confusion.

Before each use, the oral suspension must be shaken vigorously to ensure uniform distribution of the suspended active ingredient throughout the product. Drug particles settle during storage, and this settlement is a normal characteristic of suspension formulations. Failure to adequately remix the product before administration results in inconsistent dosing, with early doses potentially containing less medication than intended while subsequent doses may contain excessive amounts. This variability compromises treatment efficacy for some animals while exposing others to unnecessary drug levels, both of which are undesirable outcomes. The product should be used promptly after mixing, and the bottle should be re-shaken if significant time passes during the treatment session.

Dosing equipment requires regular maintenance to ensure accurate and consistent delivery. Drench guns and dosing syringes should be calibrated according to manufacturer instructions and checked periodically for accuracy, as wear from regular use can affect delivery precision over time. Equipment should be cleaned thoroughly after each use to prevent buildup of dried product that could impair function or contaminate subsequent treatments. Nozzles should be inspected for damage that could cause oral trauma during administration, and damaged equipment should be replaced. Proper equipment maintenance supports both treatment efficacy and animal welfare.

Disposal of empty containers and unused or expired oxfendazole products must comply with applicable local, state, and federal regulations. Empty containers should be triple-rinsed before disposal, with rinsate disposed of appropriately rather than discharged to water systems or land where environmental contamination could occur. Unused or expired product should not be disposed of through household waste or poured down drains. Manufacturer disposal instructions on the product label should be followed. Many agricultural suppliers and veterinary practices offer medication disposal programs, or local hazardous waste collection facilities may accept veterinary pharmaceutical waste. Material Safety Data Sheets provide additional guidance on safe handling and disposal.

While oxfendazole is approved for use in cattle generally rather than for specific breeds, certain breed-related and production-type considerations influence practical application of this anthelmintic in different cattle populations. The drug demonstrates consistent efficacy across the spectrum of cattle breeds when appropriate weight-based dosing is employed. Breed-specific pharmacokinetic differences or sensitivity variations have not been documented for oxfendazole in cattle, allowing broad application across the diversity of beef and dairy genetics present in the cattle industry.

The more significant distinction affecting oxfendazole use relates to production type rather than breed per se. The restriction against use in female dairy cattle of breeding age due to lack of established milk withdrawal creates a clear division between suitable applications in beef versus dairy operations. In beef cattle operations, including cow-calf, stocker, and feedlot systems, oxfendazole can be used without concern for milk residues. Beef breeds including Angus, Hereford, Charolais, Simmental, and the many composite breeds common in commercial operations are all appropriate candidates for oxfendazole treatment based on parasite status rather than breed. Dairy beef crossbreds and dairy-origin animals in beef production systems are similarly appropriate for treatment when not producing milk for human consumption.

Physiological status and production stage influence treatment considerations across all breeds. Younger cattle in their first and second grazing seasons typically carry higher parasite burdens than mature animals due to developing immunity and have not yet acquired the resistance that comes with repeated exposure. These younger animals often represent priority targets for strategic treatment. Periparturient cows experience immunosuppression that increases susceptibility to parasitism and typically show elevated fecal egg counts around calving. Strategic treatment during this period can reduce pasture contamination and protect nursing calves. Nutritional status also affects both parasite resilience and recovery following treatment; well-conditioned animals generally cope better with parasitism and respond more favorably to treatment.

Cattle under intensive management with high stocking densities on irrigated pastures often face higher parasite pressure than extensively managed rangeland cattle, affecting treatment frequency decisions regardless of breed. Similarly, cattle in humid subtropical and tropical regions typically encounter year-round parasite transmission, while temperate region cattle may have more seasonal patterns that allow for strategically timed treatments. These environmental and management factors interact with breed considerations in determining appropriate parasite control strategies incorporating oxfendazole.

Understanding the array of related anthelmintic medications available for cattle enables informed treatment selection and supports the development of effective resistance management strategies through drug class rotation. Within the benzimidazole class to which oxfendazole belongs, several alternatives exist with similar mechanisms but varying characteristics. Fenbendazole (Panacur, Safe-Guard) is closely related, sharing the same mechanism of action and similar spectrum of activity. In fact, oxfendazole and fenbendazole are metabolically interconverted within the animal's body. Fenbendazole offers certain advantages including established safety during pregnancy and approval for lactating dairy cattle at specific doses with zero-hour milk withdrawal for some formulations. Albendazole (Valbazen) is another benzimidazole option that provides additional efficacy against liver flukes, distinguishing it from oxfendazole and fenbendazole. However, albendazole carries teratogenic risks during early pregnancy and lacks dairy cattle approval, limiting its versatility.

Anthelmintics from different drug classes provide true mechanism-of-action alternatives essential for resistance management through rotation programs. The macrocyclic lactone class includes ivermectin (various brands), doramectin (Dectomax), eprinomectin (Eprinex, LongRange), and moxidectin (Cydectin). These drugs act through glutamate-gated chloride channel disruption, a completely different mechanism than benzimidazole beta-tubulin binding. Macrocyclic lactones offer broad-spectrum activity against nematodes and many external parasites but lack efficacy against tapeworms and liver flukes. Extended-release formulations of certain macrocyclic lactones provide prolonged protection appropriate for specific management situations.

The imidazothiazole class is represented by levamisole (Prohibit, Levasole), which acts through nicotinic acetylcholine receptor agonism causing spastic paralysis of parasites. Levamisole has a narrower spectrum than benzimidazoles or macrocyclic lactones but provides valuable mechanism diversity. Rotation among benzimidazoles, macrocyclic lactones, and imidazothiazoles forms the basis of conventional resistance management programs. Because resistance to one benzimidazole typically confers cross-resistance to others in the class due to their shared mechanism, rotating between oxfendazole and fenbendazole provides no resistance management benefit. True rotation requires alternating between different drug classes to reduce selection pressure for resistance development against any single mechanism.